Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Few Clouds On High-Priced, Ultra-Orphan Drug Horizon

Executive Summary

With BioMarin's Brineura hitting the market with a $702,000 annual price tag, recent experience for other high-priced rare disease drugs supports the theory that payers will accept high costs for ultra-rare pediatric disease therapies.

Advertisement

Related Content

Orphan Drug Pricing Heading To Negotiating Table in US?
Biogen’s Spinraza Needs Long-Term Confirmatory Data, Says EMA
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?
PTC Gambles On Success With Emflaza; Says Price Revision Is Needed
Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan
Orphan Drug Economics: What’s The Right Price For Rare Disease Drugs?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098650

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel